1. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis. (1st June 2016) Authors: Papp, K.A.; Menter, M.A.; Raman, M.; Disch, D.; Schlichting, D.E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J.M. Journal: British journal of dermatology Issue: Volume 174:Number 6(2016) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis. (5th April 2016) Authors: Papp, K.A.; Menter, M.A.; Raman, M.; Disch, D.; Schlichting, D.E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J.M. Journal: British journal of dermatology Issue: Volume 174:Number 6(2016) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Issue 3 (March 2017) Authors: Burge, R.; Disch, D.; Gelwicks, S.; Zhang, X.; Krege, J. Journal: Osteoporosis international Issue: Volume 28:Issue 3(2017) Page Start: 799 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗